Sabra Health Care REIT, Inc. (SBRA)
收市後：
| 前收市價 | 13.27 |
| 開市 | 13.30 |
| 買盤 | 13.21 x 3000 |
| 賣出價 | 13.70 x 900 |
| 今日波幅 | 13.18 - 13.52 |
| 52 週波幅 | 11.44 - 16.60 |
| 成交量 | |
| 平均成交量 | 2,072,115 |
| 市值 | 3.109B |
| Beta 值 (5 年，每月) | 1.28 |
| 市盈率 (最近 12 個月) | 70.84 |
| 每股盈利 (最近 12 個月) | 0.19 |
| 業績公佈日 | 2023年2月20日 - 2023年2月24日 |
| 遠期股息及收益率 | 1.20 (9.13%) |
| 除息日 | 2022年11月16日 |
| 1 年預測目標價 | 14.08 |
- InvestorPlace
The 3 Best REITs to Buy for 2023
Finding the best REITs to buy can lead to great returns if you do it right. One way to do that is by buying high-quality REITs. These investment vehicles are basically like your own little mutual fund focused on investments in real estate. If real estate values go up, your return will be greater than what a straight investment would give you. These investment vehicles are especially attractive for those looking for additional passive income. With so many available, choosing the best is really ha
- Benzinga
Can These 10%+ Dividend REITs Maintain Their Yields?
Income investors love their high-yielding dividends, but they’re not too happy when rough times force real estate investment trusts (REITs) to cut the dividends. Take a look at three REITs currently offering dividends of 10% or more and whether they can maintain these high yields in future quarters. Sabra Health Care REIT Inc. (NASDAQ: SBRA) is an Irvine, California-based healthcare REIT that specializes in skilled nursing, behavioral health and senior housing. Sabra Health Care owns 407 total f
- InvestorPlace
7 REITs to Buy Now
Editor’s note: This article is regularly updated with the latest information. Given the recent performance of the sector, now may not seem like a great time to buy real estate investment trusts (REITs). Using the Dow Jones U.S. Select REIT Index as a proxy, REITs are down about 20% year-to-date (YTD). The sharp rise in interest rates in response to high inflation is playing a big role in this decline. Growing fears that climbing interest rates will cause a recession are also factoring in. Yet, w
